nejm glp 1 GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read In the FLOW trial, researchers
Description
Learn more aboutGLP-1
(2) These statements have not been evaluated by the Food and Drug Administration
What It Means, What To Do, and When Its Dangerous
no rise in suicidality.
Lets find out
